Skip to main
CING
CING logo

Cingulate (CING) Stock Forecast & Price Target

Cingulate (CING) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Cingulate Inc. is positioned favorably within the biopharmaceutical sector due to its proprietary precision timed-release drug delivery platform, which has demonstrated significant efficacy in treating ADHD, highlighted by a Phase 3 study showing industry-leading effect sizes for CTx-1301. The company's strong balance sheet and increased probability of approval, now raised to 75%, alongside the FDA's recognition of leveraging existing efficacy and safety data, further enhance its prospects. Additionally, Cingulate's partnership with Indegene is poised to drive revenue through improved marketing solutions, indicating potential for predictable cash flows over the next three years following CTx-1301's launch.

Bears say

Cingulate Inc. faces several fundamental risks that contribute to a negative outlook on its stock. Key concerns include the potential inability to complete the timely development of its lead product, CTx-1301, for ADHD, along with uncertainties regarding regulatory approval and market penetration rates which may be slower than projected. Additionally, there is a looming dilution risk in the near- to medium-term, compounded by partnership uncertainties, particularly with the Indegene relationship, which further dampens investor confidence.

Cingulate (CING) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cingulate and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cingulate (CING) Forecast

Analysts have given Cingulate (CING) a Strong Buy based on their latest research and market trends.

According to 7 analysts, Cingulate (CING) has a Strong Buy consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.79, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.79, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cingulate (CING)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.